Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Executive Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
Fragile X Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Scientific Presentations
Publications
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
Dec 30, 2015
Appendix 3B
Dec 07, 2015
Trofinetide successful in Phase 2 trial in Fragile X
Dec 03, 2015
Trading Halt
Nov 30, 2015
Grant of composition patent in Europe for Neuren's NNZ-2591
Nov 17, 2015
Corporations Act Notice
Nov 17, 2015
Appendix 3B
Nov 09, 2015
Shareholders provide further support for Rett syndrome
Oct 29, 2015
Neuren completes enrolment in INTREPID clinical trial
Oct 21, 2015
Appendix 4C - quarterly
Oct 13, 2015
IRSF confirms financial support for Neuren's clinical trials
1
2
3
4
Next
